Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 4, 2014, Pages 279-286

  Gicquel, Thomas ^a   Victoni, Tatiana ^a   Fautrel, Alain ^a   Robert, Sacha ^a   Gleonnec, Florence ^a   Guezingar, Marie ^a   Couillin, Isabelle ^b   Catros, Véronique ^a   Boichot, Elisabeth ^a   Lagente, Vincent ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

Adenosine triphosphate; Cytokines; Inflammasome; Macrophage; NOD like receptor family protein 3; Purinergic receptors

Indexed keywords

2',3' O (4 BENZOYLBENZOYL)ADENOSINE 5' TRIPHOSPHATE; 3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; A 740003; ADENOSINE 5' [GAMMA THIO]TRIPHOSPHATE TETRALITHIUM SALT; ADENOSINE TRIPHOSPHATE DERIVATIVE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; NOD LIKE RECEPTOR PROTEIN 1; NOD LIKE RECEPTOR PROTEIN 2; NOD LIKE RECEPTOR PROTEIN 3; NOD LIKE RECEPTOR PROTEIN 4; NOD LIKE RECEPTOR PROTEIN 6; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; LUNG FIBROSIS; MACROPHAGE ACTIVATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; CYTOKINES; INFLAMMASOME; MACROPHAGE; NOD-LIKE RECEPTOR-FAMILY PROTEIN 3; PURINERGIC RECEPTORS;

ADENOSINE TRIPHOSPHATE; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; RNA, MESSENGER;

EID: 84897909297     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12214     Document Type: Article

References (31)

1. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
2. Villani AC, Lemire M, Fortin G et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 2009; 41: 71-76.
3. Rosengren S, Hoffman HM, Bugbee W, Boyle DL. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann. Rheum. Dis. 2005; 64: 708-14.
4. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25.
5. Gasse P, Riteau N, Charron S et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 903-13.
6. Riteau N, Gasse P, Fauconnier L et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 2010; 182: 774-83.
7. Gasse P, Mary C, Guenon I et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 2007; 117: 3786-99.
8. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002; 10: 417-26.
9. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-32.
10. Netea MG, Nold-Petry CA, Nold MF et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113: 2324-35.
11. Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: A key player in IL-1 processing and release. J. Immunol. 2006; 176: 3877-83.
12. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS. Activation and regulation of purinergic P2X receptor channels. Pharmacol. Rev. 2007; 63: 641-83.
13. Monção-Ribeiro LC, Cagido VR, Lima-Murad G et al. Lipopolysaccharide-induced lung injury: Role of P2X7 receptor. Respir. Physiol. Neurobiol. 2011; 179: 314-25.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
15. Okuma T, Terasaki Y, Kaikita K et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J. Pathol. 2004; 204: 594-604.
16. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 2010; 5: e8668.
17. Kanneganti TD, Lamkanfi M, Kim YG et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 2007; 26: 433-43.
18. Ali SR, Timmer AM, Bilgrami S et al. Anthrax toxin induces macrophage death by p38 MAPK inhibition but leads to inflammasome activation via ATP leakage. Immunity 2011; 35: 34-44.
19. Ward JR, West PW, Ariaans MP et al. Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms. J. Biol. Chem. 2010; 285: 23147-58.
20. Nelson DW, Gregg RJ, Kort ME et al. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 2006; 49: 3659-66.
21. Honore P, Donnelly-Roberts D, Navomic MT et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2, 2-dimethylpropyl)-2-(3, 4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 2006; 319: 1376-85.
22. McGaraughty S, Chu KL, Namovic MT et al. P2X7-related modulation of pathological nociception in rats. Neuroscience 2007; 146: 1817-28.
23. Wilson HL, Francis SE, Dower SK, Crossman DC. Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J. Immunol. 2004; 173: 1202-8.
24. Yazdi AS, Guarda G, Riteau N et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl Acad. Sci. USA 2010; 107: 19449-54.
25. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 2005; 12: 183-9.
26. Ryan LM, Rachow JW, McCarty DJ. Synovial fluid ATP: A potential substrate for the production of inorganic pyrophosphate. J. Rheumatol. 1991; 18: 716-20.
27. Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J. Cell Sci. 1999; 112: 297-305.
28. Caraccio N, Monzani F, Santini E et al. Extracellular adenosine 5′-triphosphate modulates interleukin-6 production by human thyrocytes through functional purinergic P2 receptors. Endocrinology 2005; 146: 3172-8.
29. McGeough MD, Pena CA, Mueller JL et al. Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models. J. Immunol. 2012; 189: 2707-11.
30. Aga M, Johnson CJ, Hart AP et al. Modulation of monocyte signaling and pore formation in response to agonists of the nucleotide receptor P2X(7). J. Leukoc. Biol. 2002; 72: 222-32.
31. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001; 15: 825-35.